Mission Statement, Vision, & Core Values (2026) of Bristol-Myers Squibb Company Ce.

Step into the heart of Bristol-Myers Squibb's strategic identity where a relentless focus on transforming care meets measurable scale: with operations in over 60 countries and a workforce of approximately 34,300, BMS channels its diverse portfolio across oncology, hematology, immunology and cardiovascular disease into real-world impact; the company invests about 25% of its total revenue in R&D (2023) to pursue its mission "to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases" and its vision "to be the world's leading biopharma company that transforms patients' lives through science," while living core values-Integrity, Urgency, Accountability, Innovation, Passion and Inclusion-that drive ethical action, speed for patients, ownership, bold science, relentless dedication, and a diverse culture that seeks equitable access and environmental responsibility.

Bristol-Myers Squibb Company Ce (CELG-RI) Intro

• Global footprint: operations in over 60 countries
• Workforce: approximately 34,300 employees (2023)
• Therapeutic focus: oncology, hematology, immunology, cardiovascular
• Clinical pipeline: ~90+ clinical-stage programs spanning small molecules, biologics and cell therapies

• Mission - To discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
• Vision - To transform patients' lives through the power of science, collaboration and access, aiming to be the trusted leader in delivering breakthrough therapies globally.
• Core values:
  • Integrity - ethical conduct and transparency in research, development and business practices
  • Patient focus - prioritizing patient outcomes, safety and access
  • Innovation - significant investment in R&D and cutting-edge science
  • Collaboration - cross-sector partnerships and global research alliances
  • Sustainability - reducing environmental impact and promoting responsible operations

• R&D intensity: investing roughly one quarter of revenue into research and development to fuel pipeline growth and next-generation therapies.
• Targeted areas: advancing immuno-oncology combinations, cell therapy platforms, precision medicine in hematology and immunology, and cardio-metabolic innovations.
• Partnerships: strategic collaborations with biotech and academic centers to expand modality reach and accelerate clinical programs.

• Environmental commitments: initiatives to reduce greenhouse gas emissions, improve energy efficiency and minimize waste across manufacturing and supply chains.
• Access programs: patient assistance, tiered pricing and partnerships to improve affordability and reach in underserved regions.
• Global health engagement: investments and collaborations that support health equity, epidemiologic surveillance and capacity building.

Bristol-Myers Squibb Company Ce (CELG-RI) Overview

Bristol-Myers Squibb Company Ce (CELG-RI) centers its corporate purpose on a clear, patient-first mission: 'to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases.' This mission guides strategic priorities, R&D allocation, and commercial focus across oncology, hematology, immunology, cardiovascular disease, and fibrosis.

• The phrase 'serious diseases' targets areas with high unmet medical need, including multiple cancers, hematologic disorders, and autoimmune conditions.
• 'Innovative medicines' reflects focus on novel modalities (small molecules, biologics, cell therapy combinations, and targeted therapies).
• Patient-centric outcomes drive asset prioritization, clinical endpoint selection, and post-marketing evidence generation.
• The mission has remained stable over time, providing continuity across mergers, divestitures, and portfolio transitions.

Operational and financial choices are tightly aligned with this mission. Key metrics and resources dedicated to sustaining innovation and patient impact include R&D intensity, pipeline breadth, and commercial reach.

• Strategic focus areas: oncology & hematology, immunology, cardiovascular, fibrosis.
• R&D approach: heavy translational science, biomarker-driven trials, external partnerships and acquisitions to fill strategic gaps.
• Patient access emphasis: value- and evidence-based contracting, real-world evidence generation, patient support programs.

For a deeper dive into the company's financial profile and investor implications, see: Breaking Down Bristol-Myers Squibb Company Ce Financial Health: Key Insights for Investors

Bristol-Myers Squibb Company Ce (CELG-RI) - Mission Statement

• Prioritize scientific innovation to discover and develop medicines that address high unmet medical needs.
• Ensure patient-centric access and affordability across geographies and therapeutic areas.
• Foster collaborations with academic, biotech, and health-system partners to accelerate translational science.
• Operate with integrity, safety, and compliance while generating sustainable shareholder value.

• Leadership in scientific innovation as a core competitive differentiator, reflected in sustained R&D investment.
• Commitment to measurable improvements in patient outcomes - from survival and durable responses to quality-of-life metrics.
• Research-driven solution focus: advancing molecular science, immuno-oncology, cell therapy, and precision medicine.
• Long-term alignment of portfolio, capital allocation, and partnerships to maximize patient impact and enterprise growth.

• High and sustained R&D spend to maintain a leading clinical-stage portfolio and first-in-class opportunities.
• Targeted M&A and alliance activity to acquire novel modalities and accelerate late-stage assets.
• Investment in manufacturing and cell-therapy capacity to support commercial scalability of complex biologics.
• Data-driven commercialization and outcomes evidence generation to demonstrate real-world patient benefit.

Bristol-Myers Squibb Company Ce (CELG-RI) - Vision Statement

• Deliver transformational medicines to patients with serious diseases by prioritizing high unmet medical needs.
• Operate with speed and scientific rigor to shorten development timelines while maintaining safety and quality.
• Build an inclusive, diverse workforce that fosters creativity, rapid problem-solving, and equitable access to care.

• Integrity - Uphold ethics, quality, and transparency in all interactions with patients, providers, regulators, and colleagues. This underpins clinical trial conduct, reporting, and product quality assurance.
• Urgency - Act with speed and focus because patients are waiting; prioritize milestones that accelerate patient access to therapies.
• Accountability - Take ownership of commitments, deliver on clinical and commercial promises, and provide clear metrics and reporting to stakeholders.
• Innovation - Pursue bold, disruptive scientific approaches, invest in cutting-edge modalities (e.g., cell therapy, targeted oncology, immuno-oncology) and external partnerships to expand the pipeline.
• Passion - Demonstrate relentless dedication to learning and excellence across discovery, development, and patient support programs.
• Inclusion - Foster a workplace where diverse perspectives drive better decisions and where all employees can contribute at full potential.

• Advance a balanced portfolio of near-, mid-, and long-term programs to sustain growth and patient impact.
• Allocate significant resources to R&D and external innovation to replenish and expand high-value assets.
• Scale global manufacturing and supply chain resilience to ensure uninterrupted patient access.
• Strengthen real-world evidence generation and patient support services to demonstrate value and improve outcomes.

• Integrity → rigorous compliance, transparent safety reporting, and quality systems across manufacturing sites.
• Urgency → compressed clinical development timelines for priority assets and accelerated regulatory engagements.
• Accountability → measurable KPIs tied to clinical milestones, commercial performance, and patient access objectives.
• Innovation → strategic M&A, partnerships, and internal discovery programs targeting first-in-class and best-in-class therapies.
• Passion → talent development programs, learning ecosystems, and performance recognition aligned with patient impact.
• Inclusion → diversity goals in hiring, clinical trial population representation efforts, and supplier diversity initiatives.

• Robust external collaborations with academic centers, biotechnology companies, and consortia to de-risk novel science and expand therapeutic modalities.
• Investments in manufacturing capacity and digital platforms to improve productivity and patient-centric services.